Vicarious Surgical (RBOT) AI Stock Analysis

• Market Cap: $50.23M
• Dividend Yield: N/A
• Average Volume (3M): 21.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.79
• Revenue Growth: N/A
• EPS Growth: -1455.58%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Devices
• EPS (TTM): -7.94
• Shares Outstanding: 5,276,612
• 10 Day Avg. Volume: 19,217
• 30 Day Avg. Volume: 21,399
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.75
• Price Target Upside: 26.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Vicarious Surgical's overall score reflects significant financial challenges, including zero revenue, high cash burn, and operational delays. Technical analysis indicates bearish momentum, while valuation metrics remain unattractive. Recent corporate events add further risk, although strategic advancements and leadership changes offer potential positive developments. The company's future heavily depends on successful clinical trials and supply chain management.

Positive Factors

Cash Management

RBOT continues to manage its cash position responsibly, with cash management remaining a key priority ahead of key milestones for its robotic platform.

Financial Outlook

The new price target of $13 reflects a positive outlook, increasing from the previous target of $10, based on future sales estimates and a discount rate.

Product Development

RBOT is taking positive steps toward treating its first clinical patient.

Negative Factors

Financing Challenges

The company will need to either reduce cash burn or find some sources of non-dilutive financing.

Leadership Challenges

The CFO departure is seen as another challenge for RBOT to handle on its path towards gaining clearance.

Product Development Delays

Development milestones and timelines were shifted back 3 to 6 months due to supplier dynamics which have limited key parts within the Vicarious System.

Vicarious Surgical Business Overview & Revenue Model

Company Description

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Vicarious Surgical makes money primarily through the sale and leasing of its robotic surgical systems to hospitals and surgical centers. The company may also generate revenue through service contracts and maintenance agreements, ensuring the optimal functionality of its robotic platforms. Additionally, Vicarious Surgical could engage in strategic partnerships with healthcare providers and institutions to expand the adoption of its technology. These partnerships may involve collaborative research, co-development of surgical techniques, and training programs for surgeons. Furthermore, as the company's technology advances, it may explore revenue opportunities through software licensing, offering AI-driven analytics and insights as a service to enhance surgical performance and patient outcomes.

Vicarious Surgical Financial Statement Overview

Summary

Vicarious Surgical is in its early developmental phase, characterized by zero revenue and significant operating losses. The balance sheet remains stable with low leverage, but the cash flows highlight operational cash burn, necessitating ongoing financing. Strategic focus on product development and future revenue generation will be crucial for financial improvement.

Income Statement

Vicarious Surgical has reported zero revenue consistently, indicating a pre-revenue stage company. This lack of revenue growth severely impacts the ability to assess profitability metrics like gross and net profit margins, which remain negative due to high operating losses.

Balance Sheet

The balance sheet reflects a moderate leverage position with a debt-to-equity ratio of 0.30 in 2024, highlighting a manageable level of debt. However, declining equity due to persistent losses could pose future risks. The positive equity ratio of 68.95% suggests some stability in financial structure despite challenges.

Cash Flow

The company demonstrates negative free cash flow, indicating cash outflows exceed operating inflows, which is typical for a development-stage firm. The negative operating cash flow to net income ratio shows operational challenges, though cash reserves have been bolstered through financing activities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-1.85M	-1.94M	-316.00K	0.00
	EBIT
-66.56M	-80.67M	-80.08M	-38.57M	-12.98M
	EBITDA
-66.56M	-69.19M	7.30M	-34.80M	-161.18K
	Net Income Common Stockholders
-63.22M	-71.07M	89.16M	-7.04M	-12.88M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
49.10M	98.18M	116.21M	173.51M	16.87M
	Total Assets
67.72M	119.86M	140.29M	181.69M	17.79M
	Total Debt
13.79M	14.83M	15.69M	1.34M	110.00K
	Net Debt
4.05M	-37.99M	-100.52M	-172.17M	-16.76M
	Total Liabilities
21.02M	21.89M	29.25M	98.95M	935.00K
	Stockholders Equity
46.70M	97.97M	111.05M	82.74M	16.85M
Cash Flow		Free Cash Flow
-50.14M	-63.98M	-66.56M	-34.59M	-12.16M
	Operating Cash Flow
-49.96M	-62.30M	-61.21M	-33.30M	-12.04M
	Investing Cash Flow
6.86M	-45.78M	-5.35M	-1.29M	13.20M
	Financing Cash Flow
8.00K	44.70M	9.14M	192.16M	13.52M

Vicarious Surgical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Neutral. The current price of 8.47 is above the 20-day moving average (MA) of 5.86, below the 50-day MA of 8.63, and below the 200-day MA of 9.26, indicating a neutral trend. The MACD of -0.49 indicates Negative momentum. The RSI at 64.62 is Neutral, neither overbought nor oversold. The STOCH value of 77.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RBOT.

Vicarious Surgical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIBN	60 Neutral	$611.75M	―	-18.38%	―	20.37%	34.10%
PRCT	58 Neutral	$2.88B	―	-27.62%	―	59.36%	19.87%
KIDS	55 Neutral	$534.87M	―	-10.34%	―	37.65%	-77.01%
TLSI	53 Neutral	$184.92M	―	271.41%	―	169.66%	28.89%
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
RXST	47 Neutral	$607.27M	―	-12.43%	―	57.08%	49.93%
RBOT	30 Underperform	$50.23M	―	-87.40%	―	―	-1455.58%

Vicarious Surgical Corporate Events

Vicarious Surgical Faces NYSE Non-Compliance Notice

On April 10, 2025, Vicarious Surgical received a notice from the NYSE indicating non-compliance with listing standards due to its market capitalization and stockholders’ equity both being below $50 million. The company has 45 days to submit a compliance plan to the NYSE, which, if accepted, will allow its stock to continue trading with a ‘.BC’ designation indicating below-criteria status. This notice does not affect the company’s operations or SEC reporting obligations, and Vicarious Surgical is exploring options to regain compliance.

Spark’s Take on RBOT Stock

According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.

The overall score for Vicarious Surgical’s stock is 38, reflecting significant financial challenges due to its early-stage status with zero revenue and high cash burn. Technical indicators point to bearish momentum, while valuation remains unattractive with a negative P/E. The earnings call highlighted both strategic advancements and operational delays, balancing the outlook slightly. The company’s future relies on successful clinical trials and managing supply chain issues.

To see Spark’s full report on RBOT stock, click here.

Vicarious Surgical Appoints New Chief Financial Officer

On March 13, 2025, Vicarious Surgical announced the appointment of Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano, with over two decades of financial experience, is expected to leverage her expertise in financial strategy and corporate development to drive the company’s financial objectives and success, particularly as Vicarious Surgical approaches its first clinical use cases later this year.

Vicarious Surgical Announces COO Retirement in 2025

On February 12, 2025, Vicarious Surgical announced the planned retirement of its Chief Operating Officer, John Mazzola, effective April 1, 2025. Mazzola, who has nearly 40 years of experience in healthcare manufacturing and quality control, has been pivotal in advancing the company’s manufacturing processes and supply chain resilience, positioning Vicarious Surgical for upcoming clinical use cases and trials. His responsibilities will transition to Randy Clark, the company’s President.